Viking Therapeutics (VKTX) Non Operating Investment Income (2024)

Viking Therapeutics (VKTX) reported Non Operating Investment Income of $1000.0 for Q4 2024, down 99.08% sequentially from $109000.0 in Q3 2024.

Viking Therapeutics (VKTX) Non Operating Investment Income (2024) Analysis & Trends

Viking Therapeutics (VKTX) has 1 years of Non Operating Investment Income data on file, last reported at $1000.0 in Q4 2024.

For the quarter ending Q4 2024, Non Operating Investment Income changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2024 stood at $112000.0 (changed N/A YoY), and the FY2025 full-year result was $55000.0, down 50.89% from the prior year.
Non Operating Investment Income slipped to $1000.0 in Q4 2024, from $109000.0 in the prior quarter.
In the past five years, Non Operating Investment Income ranged from a high of $109000.0 in Q3 2024 to a low of $1000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Viking Therapeutics	4.09 Bn	4.09 Bn	-	-

Download Data